中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 8
Aug.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(8): 1974-1979

Pathogenesis and treatment of craniopharyngioma-related liver diseases

DOI: 10.12449/JCH260834

  • Department of Endocrinology，Shanxi Provincial People’s Hospital Affiliated to Shanxi Medical University，Taiyuan 030012，China

Research funding:

Four “Batches” Innovation Project of Invigorating Medical Through Science and Technology of Shanxi Province (2023XM0482023XM048)

More Information
  • Corresponding author: Qin Jie， hopejieqin@sohu.com （ORCID： 0000-0002-7249-093X）
  • Received Date: 2025-11-12
  • Accepted Date: 2026-03-02
  • Published Date: 2026-08-25
    Abstract
  • Patients with craniopharyngioma are at a high risk of developing metabolic dysfunction-associated fatty liver disease and its severe complications， yet this association is often neglected in clinical practice， with a lack of systematic reviews. This article systematically reviews the clinical spectrum and epidemiological characteristics of liver diseases associated with craniopharyngioma， with a focus on their core pathogenic mechanisms， and it also summarizes current tumor treatment strategies aimed at preventing hypothalamic injury and highlights that establishing a multidisciplinary collaborative diagnosis and treatment model and implementing early intervention are key to improving prognosis. Future research should focus on elucidating the precise pathways through which hypothalamic injury leads to metabolic disturbances， thereby facilitating the development of targeted therapies， in order to provide new directions for fundamentally improving the clinical outcomes of these patients.

     

    • FullText(HTML)
  • loading
    • References(49)
  • [1]
    Beckhaus J, Friedrich C, Müller H L. Vascular morbidity and mortality in craniopharyngioma patients-a scoping review[J]. Cancers, 2024, 16( 6): 1099. DOI: 10.3390/cancers16061099.
    [2]
    Wu J, Wu X, Yang Y Q, et al. Association of histological subtype with risk of recurrence in craniopharyngioma patients: A systematic review and meta-analysis[J]. Neurosurg Rev, 2022, 45( 1): 139- 150. DOI: 10.1007/s10143-021-01563-9.
    [3]
    Hoffmann A, Bootsveld K, Gebhardt U, et al. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma[J]. Eur J Endocrinol, 2015, 173( 3): 389- 397. DOI: 10.1530/EJE-15-0422.
    [4]
    Jung S Y, Lee Y J, Lee H J, et al. Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma[J]. Ann Pediatr Endocrinol Metab, 2017, 22( 3): 189- 196. DOI: 10.6065/apem.2017.22.3.189.
    [5]
    Jung D, Seo G H, Kim Y M, et al. Hepatopulmonary syndrome caused by hypothalamic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma: A case report[J]. Ann Pediatr Endocrinol Metab, 2018, 23( 1): 51- 55. DOI: 10.6065/apem.2018.23.1.51.
    [6]
    Mazerkina N A, Savateev A N, Gorelyshev S K, et al. Hepatopulmonary syndrome: A rare manifestation of cirrhosis in patient with diencephalic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma[J]. Probl Endokrinol, 2021, 67( 5): 58- 66. DOI: 10.14341/probl12723.
    [7]
    Scarano E, Solari D, Riccio E, et al. Craniopharyngioma and metabolic syndrome: A 5-year follow-up single-center experience[J]. Front Neurol, 2022, 13: 783737. DOI: 10.3389/fneur.2022.783737.
    [8]
    Erfurth E M. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy[J]. J Intern Med, 2023, 294( 3): 269- 280. DOI: 10.1111/joim.13684.
    [9]
    Ni W M, Shi X E. Interventions for the treatment of craniopharyngioma-related hypothalamic obesity: A systematic review[J]. World Neurosurg, 2018, 118: e59- e71. DOI: 10.1016/j.wneu.2018.06.121.
    [10]
    Ashhab A A, Albrecht J, Debes J D. The way to the liver is through the pituitary gland[J]. Am J Gastroenterol, 2018, 113( 1): 145- 146. DOI: 10.1038/ajg.2017.434.
    [11]
    Roth C L, McCormack S E. Acquired hypothalamic obesity: A clinical overview and update[J]. Diabetes Obes Metab, 2024, 26( S2): 34- 45. DOI: 10.1111/dom.15530.
    [12]
    Romigi A, Feola T, Cappellano S, et al. Sleep disorders in patients with craniopharyngioma: A physiopathological and practical update[J]. Front Neurol, 2021, 12: 817257. DOI: 10.3389/fneur.2021.817257.
    [13]
    Castro D C, Cole S L, Berridge K C. Lateral hypothalamus, nucleus accumbens, and ventral pallidum roles in eating and hunger: Interactions between homeostatic and reward circuitry[J]. Front Syst Neurosci, 2015, 9: 90. DOI: 10.3389/fnsys.2015.00090.
    [14]
    McCormack S E, Blevins J E, Lawson E A. Metabolic effects of oxytocin[J]. Endocr Rev, 2020, 41( 2): 121- 145. DOI: 10.1210/endrev/bnz012.
    [15]
    Lee M, Park M J, Lee K H, et al. Obesity mechanism after hypothalamic damage: Cohort analysis of neuroimaging, psychological, cognitive, and clinical phenotyping data[J]. Front Endocrinol, 2023, 14: 1114409. DOI: 10.3389/fendo.2023.1114409.
    [16]
    Wu W, Sun Q Y, Zhu X M, et al. Risk factors for hypothalamic obesity in patients with adult-onset craniopharyngioma: A consecutive series of 120 cases[J]. Front Endocrinol, 2021, 12: 694213. DOI: 10.3389/fendo.2021.694213.
    [17]
    Mushtaq A, Fayaz M, Bhat A R, et al. Comprehensive analysis of craniopharyngioma: Epidemiology, clinical characteristics, management strategies, and role of radiotherapy[J]. Cancer Diagn Progn, 2024, 4( 4): 521- 528. DOI: 10.21873/cdp.10358.
    [18]
    Yang Y, Qi Z R, Zhang T T, et al. Rapidly progressive non-alcoholic fatty liver disease due to hypopituitarism. Report of 5 cases[J]. Neuro Endocrinol Lett, 2018, 39( 2): 99- 104.
    [19]
    Kang S J, Kwon A, Jung M K, et al. High prevalence of nonalcoholic fatty liver disease among adolescents and young adults with hypopituitarism due to growth hormone deficiency[J]. Endocr Pract, 2021, 27( 11): 1149- 1155. DOI: 10.1016/j.eprac.2021.06.003.
    [20]
    Das L, Sahoo J, Dahiya N, et al. Long-term hepatic and cardiac health in patients diagnosed with Sheehan’s syndrome[J]. Pituitary, 2022, 25( 6): 971- 981. DOI: 10.1007/s11102-022-01282-4.
    [21]
    Xiao J F, Zhu C G, Zhang X X, et al. Associations among FT4 level, FT3/FT4 ratio, and non-alcoholic fatty liver disease in Chinese patients with hypopituitarism[J]. Endocr J, 2022, 69( 6): 659- 667. DOI: 10.1507/endocrj.EJ21-0536.
    [22]
    Lonardo A, Mantovani A, Lugari S, et al. NAFLD in some common endocrine diseases: Prevalence, pathophysiology, and principles of diagnosis and management[J]. Int J Mol Sci, 2019, 20( 11): 2841. DOI: 10.3390/ijms20112841.
    [23]
    Kander M C, Cui Y Q, Liu Z G. Gender difference in oxidative stress: A new look at the mechanisms for cardiovascular diseases[J]. J Cell Mol Med, 2017, 21( 5): 1024- 1032. DOI: 10.1111/jcmm.13038.
    [24]
    Zhang P Z, Ge Z J, Wang H D, et al. Prolactin improves hepatic steatosis via CD36 pathway[J]. J Hepatol, 2018, 68( 6): 1247- 1255. DOI: 10.1016/j.jhep.2018.01.035.
    [25]
    Vázquez-Borrego M C, Del Río-Moreno M, Pyatkov M, et al. Direct and systemic actions of growth hormone receptor(GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis[J]. Metabolism, 2023, 144: 155589. DOI: 10.1016/j.metabol.2023.155589.
    [26]
    Ishikawa M, Brooks A J, Fernández-Rojo M A, et al. Growth hormone stops excessive inflammation after partial hepatectomy, allowing liver regeneration and survival through induction of H2-bl/HLA-G[J]. Hepatology, 2021, 73( 2): 759- 775. DOI: 10.1002/hep.31297.
    [27]
    Soler Palacios B, Nieto C, Fajardo P, et al. Growth hormone reprograms macrophages toward an anti-inflammatory and reparative profile in an MAFB-dependent manner[J]. J Immunol, 2020, 205( 3): 776- 788. DOI: 10.4049/jimmunol.1901330.
    [28]
    Kong T T, Gu Y P, Sun L, et al. Association of nonalcoholic fatty liver disease and growth hormone deficiency: A systematic review and meta-analysis[J]. Endocr J, 2023, 70( 10): 959- 967. DOI: 10.1507/endocrj.EJ23-0157.
    [29]
    Hwang Y A, Lee H W, Ahn S H, et al. Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma[J]. Front Endocrinol, 2022, 13: 1057769. DOI: 10.3389/fendo.2022.1057769.
    [30]
    Zhang Y W, Chen P Z, Fang X Q. Proteomic and metabolomic analysis of GH deficiency-induced NAFLD in hypopituitarism: Insights into oxidative stress[J]. Front Endocrinol, 2024, 15: 1371444. DOI: 10.3389/fendo.2024.1371444.
    [31]
    Hassani Zadeh S, Mansoori A, Hosseinzadeh M. Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36( 6): 1470- 1478. DOI: 10.1111/jgh.15363.
    [32]
    Younossi Z M, Corey K E, Lim J K. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review[J]. Gastroenterology, 2021, 160( 3): 912- 918. DOI: 10.1053/j.gastro.2020.11.051.
    [33]
    Gao Y, Zhang W, Zeng L Q, et al. Exercise and dietary intervention ameliorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy[J]. Redox Biol, 2020, 36: 101635. DOI: 10.1016/j.redox.2020.101635.
    [34]
    Babu A F, Csader S, Lok J, et al. Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: A systematic review and meta-analysis[J]. Nutrients, 2021, 13( 9): 3135. DOI: 10.3390/nu13093135.
    [35]
    Oh S, Tsujimoto T, Kim B, et al. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD[J]. JHEP Rep, 2021, 3( 3): 100253. DOI: 10.1016/j.jhepr.2021.100253.
    [36]
    Otte A, Müller H L. Childhood-onset craniopharyngioma[J]. J Clin Endocrinol Metab, 2021, 106( 10): e3820- e3836. DOI: 10.1210/clinem/dgab397.
    [37]
    Ganau M, Foroni R I, Gerosa M, et al. Radiosurgical options in neuro-oncology: A review on current tenets and future opportunities. Part I: Therapeutic strategies[J]. Tumori, 2014, 100( 4): 459- 465. DOI: 10.1700/1636.17912.
    [38]
    Horne V E, Bielamowicz K, Nguyen J, et al. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity[J]. Pediatr Blood Cancer, 2020, 67( 7): e28379. DOI: 10.1002/pbc.28379.
    [39]
    Kelly A S, Bensignor M O, Hsia D S, et al. Phentermine/topiramate for the treatment of adolescent obesity[J]. NEJM Evid, 2022, 1( 6): 10.1056/evidoa 2200014. DOI: 10.1056/evidoa2200014.
    [40]
    Greenway F L, Bray G A. Treatment of hypothalamic obesity with caffeine and ephedrine[J]. Endocr Pract, 2008, 14( 6): 697- 703. DOI: 10.4158/EP.14.6.697.
    [41]
    Huynh K, Klose M, Krogsgaard K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity[J]. Eur J Endocrinol, 2022, 186( 6): 687- 700. DOI: 10.1530/EJE-21-0972.
    [42]
    van Schaik J, Welling M S, de Groot C J, et al. Dextroamphetamine treatment in children with hypothalamic obesity[J]. Front Endocrinol, 2022, 13: 845937. DOI: 10.3389/fendo.2022.845937.
    [43]
    van Santen H M, Denzer C, Müller H L. Could setmelanotide be the game-changer for acquired hypothalamic obesity?[J]. Front Endocrinol, 2023, 14: 1307889. DOI: 10.3389/fendo.2023.1307889.
    [44]
    Shoemaker A H, Silver H J, Buchowski M, et al. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist[J]. Int J Obes(Lond), 2022, 46( 3): 623- 629. DOI: 10.1038/s41366-021-01043-6.
    [45]
    McCormack S E, Wang Z, Wade K L, et al. A pilot randomized clinical trial of intranasal oxytocin to promote weight loss in individuals with hypothalamic obesity[J]. J Endocr Soc, 2023, 7( 5): bvad037. DOI: 10.1210/jendso/bvad037.
    [46]
    Svendstrup M, Rasmussen A K, Kistorp C, et al. Semaglutide treatment of hypothalamic obesity—a real-life data study[J]. Pituitary, 2024, 27( 5): 685- 692. DOI: 10.1007/s11102-024-01429-5.
    [47]
    Pan C S, Weiss J J, Fourman L T, et al. Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease[J]. Clin Endocrinol, 2021, 94( 2): 183- 192. DOI: 10.1111/cen.14344.
    [48]
    Zhang X Y, Yuan K, Fang Y L, et al. Growth hormone ameliorates hepatopulmonary syndrome and nonalcoholic steatohepatitis secondary to hypopituitarism in a child: A case report[J]. World J Clin Cases, 2022, 10( 18): 6211- 6217. DOI: 10.12998/wjcc.v10.i18.6211.
    [49]
    Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy[J]. Eur J Endocrinol, 2012, 167( 1): 67- 74. DOI: 10.1530/EJE-12-0252.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (10) PDF downloads(0) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return